Project Grant HT94252410440
Award Date
6/1/24
Completion Date
5/31/28
Dollars Obligated
$1.8M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Great Britain, United Kingdom
Similar Awards
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
This federal Project Grant award of $299,999.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is funding research at the Institute of Cancer Research: Royal Cancer Hospital (The) in the United Kingdom. The award aims to enhance the efficacy of BH3 mimetics, a class of cancer therapeutic drugs, to induce apoptosis (programmed cell death) in lethal prostate cancer. The performance period for this award is June 1, 2024 through May 31, 2026. As a...
The federal Project Grant award in the amount of $499,999.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), funds research by the Institute of Cancer Research: Royal Cancer Hospital (The) to study the interplay of molecular and spatial architectures with clinical states in prostate cancer. The research project aims to make discoveries that defeat cancer through innovative biomedical research. As a subawardee, the Institute of...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
The Department of the Army Medical Command awarded a $541,681 project grant to Dana-Farber Cancer Institute, Inc. to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. This award falls under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical solutions for battlefield...
The Department of Defense (DoD) has awarded a $846,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Institute For Cancer Research, a non-profit research organization, to investigate PALB2 mutant breast cancer. The funding supports a 3-year research project from August 1, 2024 to July 31, 2027. As the prime grantee, The Institute For Cancer Research will conduct innovative scientific studies and clinical trials focused on developing new treatments...
The Department of the Army Medical Command awarded a $2,247,531 project grant to The Children's Hospital of Philadelphia through the Military Medical Research and Development program (CFDA 12.420) to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. The four-year project beginning September 1, 2022 will apply basic, applied, and advanced biomedical research approaches to transform pediatric cancer care and investigate...
The Project Grant award of $624,000 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) federal grant program to the Research Institute at Nationwide Children's Hospital. The funding supports a project titled "SPLICING UP PD-L1 FOR IMMUNOTHERAPY ENHANCEMENT IN PEDIATRIC NEURONAL TUMORS" over a two-year period from September 30, 2023 to September 29, 2025. The goal is to conduct research to advance immunotherapy approaches...
The University Health Network will receive $1,419,453 under a Project Grant award from the Department of the Army Medical Command to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. Funded through the Military Medical Research and Development program (CFDA 12.420), this four-year award beginning September 1, 2022 will support applied research investigating medical solutions for neuroblastoma on the battlefield and...
The federal Project Grant award of $438,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research conducted by the Provincial Health Services Authority in Canada, operating under the name BC Cancer, to decode and target genomic instability in pediatric osteosarcoma. The project, with a period of performance from September 30, 2023 to September 29, 2025, aims to develop innovative solutions for cancer treatment,...